Cerevel Therapeutics Holdings, Inc. (CERE)
| Market Cap | 1.72B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 127.12M |
| EPS (ttm) | -27.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 26 |
| Last Price | $13.15 |
| Previous Close | $13.42 |
| Change ($) | -0.27 |
| Change (%) | -2.01% |
| Day's Open | 13.43 |
| Day's Range | 12.79 - 14.46 |
| Day's Volume | 227,460 |
| 52-Week Range | 9.82 - 18.27 |
News
Event will focus on CVL-865, the Phase 2 GABA Positive Allosteric Modulator, and include an overview of key preclinical programs
CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced ...
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced ...
About CERE
Cerevel Therapeutics Holdings operates as a clinical-stage biopharmaceutical company that engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in an ongoing Phase Ib multiple ascending dose and pharmacokinetic/pharmacodynamic trials for the treatment of patients with schizophrenia; and CVL-865, a PAM that is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as intends to initiate a P... [Read more...]
| Industry Biotechnology | Founded 2018 |
| CEO Dr. N. Anthony Coles Jr. | Employees 100 |
| Stock Exchange NASDAQ | Ticker Symbol CERE |
Analyst Forecasts
The average 12-month stock price forecast for CERE is 22.33, which is an increase of 69.81% from the latest price.